Rigosertib was first developed as a non-ATP competitive, multi-kinase inhibitor, and although it exhibits some ability to bind the Raf RBD, this drug is broadly cytotoxic in many cancer lines (Reddy et al, 2011). The gene discussed is RAF1; the disease is cancer.